To date, EGFR blockades are attractive targets in HNSCC patients and anti-EGFR strategies such as IgG-based monoclonal antibodies (mAbs), have shown acceptable clinical benefits. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.